Danaher Corp
DHRQ4 2022(DHR Q3 FY2022)Estimated1% AI
AI Revenue %
1%
AI Fair Value
$640.1M
AI Revenue (Q)
$76.6M
Total Revenue (Q)
$7.7B
Source: SEC EDGAR 10-Q Filing
View 10-Q on SEC.govAnalysis
Q3 FY2022 (three-month period ended September 30, 2022). Total sales $7,663M. Segments: Life Sciences $3,776M, Diagnostics $2,679M, Environmental & Applied Solutions $1,208M. No AI revenue disclosure. No mention of AI or machine learning in the filing. Same rationale as Q2: DHR instruments contain embedded software algorithms for analysis, but are fundamentally hardware/reagent businesses. Conservative 1% estimate for embedded algorithmic content. Math: ~$77M estimated / $7,663M total = ~1.0%.
Analyzed by claude-opus-4-6
Quoted Figures
Sales $7,663 [three-month period ended September 30, 2022]
10-Q Q3 FY2022, Consolidated Condensed Statements of Earnings
Life Sciences $3,776; Diagnostics $2,679; Environmental & Applied Solutions $1,208 [three-month period ended September 30, 2022]
10-Q Q3 FY2022, Note 6 Segment Information
AI Products Identified (Ring 1)
Embedded instrument algorithms (digital pathology, flow cytometry, clinical chemistry)
AI-Enabled Items (Ring 2 — Not Counted)
These items use AI but are not counted in the AI revenue estimate because they primarily serve non-AI functions.
Life Sciences instrumentsDiagnostics instrumentsBiotechnology consumablesEnvironmental & Applied Solutions
Confidence Tier
EstimatedNo direct AI revenue disclosure — estimated from product mix